Please use this identifier to cite or link to this item:
https://hdl.handle.net/11147/13325
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Çetinkaya, Melisa | - |
dc.contributor.author | Baran, Yusuf | - |
dc.date.accessioned | 2023-04-19T12:37:47Z | - |
dc.date.available | 2023-04-19T12:37:47Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | https://doi.org/10.3390/vaccines11030554 | - |
dc.identifier.uri | https://hdl.handle.net/11147/13325 | - |
dc.description.abstract | Cancer is a global concern, as the rate of incidence is increasing each year. The challenges related to the current chemotherapy drugs, such as the concerns related to toxicity, turn to cancer therapeutic research to discover alternative therapy strategies that are less toxic to normal cells. Among those studies, the use of flavonoids-natural compounds produced by plants as secondary metabolites for cancer therapy-has been a hot topic in cancer treatment. Luteolin, a flavonoid that has been present in many fruits, vegetables, and herbs, has been identified to exhibit numerous biological activities, including anti-inflammatory, antidiabetic, and anticancer properties. The anticancer property of Luteolin has been extensively researched in many cancer types and has been related to its ability to inhibit tumor growth by targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression. It achieves this by interacting with various signaling pathways and proteins. In the current review, the molecular targets of Luteolin as it exerts its anticancer properties, the combination therapy that includes Luteolin with other flavonoids or chemotherapeutic drugs, and the nanodelivery strategies for Luteolin are described for several cancer types. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartof | Vaccine | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Flavonoids | en_US |
dc.subject | Luteolin | en_US |
dc.subject | Anticancer | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Cell cycle regulation | en_US |
dc.subject | Angiogenesis | en_US |
dc.subject | Metastasis | en_US |
dc.subject | Nanodelivery systems | en_US |
dc.subject | miRNAs | en_US |
dc.title | Therapeutic potential of luteolin on cancer | en_US |
dc.type | Review | en_US |
dc.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.wos | WOS:000958238000001 | en_US |
dc.identifier.scopus | 2-s2.0-85151557629 | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.doi | 10.3390/vaccines11030554 | - |
dc.identifier.pmid | 36992138 | en_US |
dc.authorscopusid | 58169672700 | - |
dc.authorscopusid | 9636164400 | - |
dc.identifier.wosquality | Q1 | - |
dc.identifier.scopusquality | Q2 | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Review | - |
crisitem.author.dept | 04.03. Department of Molecular Biology and Genetics | - |
Appears in Collections: | Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
vaccines-11-00554.pdf | 2.84 MB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
50
checked on Nov 15, 2024
WEB OF SCIENCETM
Citations
41
checked on Nov 9, 2024
Page view(s)
166
checked on Nov 18, 2024
Download(s)
74
checked on Nov 18, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.